Profitelligence Profitelligence · Filing Ledger Open TWST research →

Form 8-K · Current Report · Filed 2026-08-18

Twist Bioscience Selected as Evaluator for Anthropic's AI-Driven Protein Design Campaign

On August 18, 2026, Twist Bioscience Corporation announced that it has been selected by Anthropic, PBC as one of its independent evaluators for a multi-arm protein design campaign.

Filer
Twist Bioscience Corporation TWST · NASDAQ
Filed
Accession
0001581280-26-000050
CIK
0001581280
Signal
Medium impactHealthcare

Details

This campaign, which utilizes AI models Claude Opus 4.8 and Mythos Preview, aims to rapidly produce and test AI-designed proteins against 15 targets for binding. This partnership highlights Twist Bioscience's role in advancing AI-driven protein research.

Items reported

Item events

Reported Item

Strategic Partnership Regulation FD Disclosure

Market reaction

Close before filing

$124.41

Next session

+14.5%

Since filing

+25.0%

Latest close

$155.56

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from TWST reporting the same item, with the next session's move:

Twist Bioscience Announces $300 Million Public Offering of Common Stock+9.7%
Twist Bioscience Reports 23% Revenue Growth and Raises Full-Year Guidance+8.6%
Twist Bioscience Reports Strong Q2 2026 Financial Results and Raises Guidance-6.1%
Twist Bioscience Corporation Announces Share Issuance in Stock Purchase Agreements+11.8%
Twist Bioscience Shareholders Approve Key Proposals+0.8%

Insider tape

Within 45 days of this filing, TWST insiders reported 44 Form 4 transactions — net selling of $36.8M.

Full TWST insider history →

About Twist Bioscience Corporation

Twist Bioscience Corporation is a pioneering biotechnology firm revolutionizing the field of synthetic DNA. The company's primary function is to produce synthetic DNA using a proprietary silicon-based manufacturing platform, enabling the creation of high-quality, accurate, and cost-effective DNA at scale. Twist Bioscience's innovations impact multiple sectors, including pharmaceuticals, industrial chemicals, agriculture, and data storage, offering transformative solutions in drug development, crop protection, and genomic research. By leveraging its proprietary DNA synthesis platform, Twist Bioscience plays a vital role in the broader biotechnology market, facilitating advancements that drive progress in personalized medicine and sustainable practices. With its cutting-edge technology, the company provides researchers and businesses with access to a wide array of DNA products and solutions essential for scientific discovery and technological innovation, underpinning its significance in the expanding biotech landscape.

Exchange NASDAQ Industry Diagnostics & Research Company website ↗

Never miss another TWST filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts